Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Key Highlights
- ➤Edgewise Therapeutics (EWTX) granted options covering 7,500 common shares.
- ➤Edgewise Therapeutics (EWTX) granted restricted stock units covering 3,751 shares.
- ➤Three new non-executive employees received inducement equity awards.
- ➤Inducement options carry a $40.60-per-share exercise price.
- ➤Awards were issued under Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on September 30, 2026, Edgewise granted inducement stock options to purchase a total of 7,500 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 3,751 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
Get started
Create a free account to read the full story.